Alzinova AB (publ) (“Alzinova” or “the Company”), hereby announces that the Company has entered into an agreement with Redeye AB (“Redeye”) regarding the service as Certified Adviser. Redeye will be appointed Certified Adviser (CA) on December 1st, 2022. Until then, Corpura Fondkommission AB will continue to act as Certified Adviser for the Company.

For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail:  kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Corpura. For more information about Alzinova, please visit: www.alzinova.com

Attachments
Alzinova announces change of Certified Adviser

© Modular Finance, source Nordic Press Releases